Rheumatoid arthritis specific antigen

Abstract

The invention relates to the medical field, and in particular relates to superoxide reductase IV used in the preparation of a rheumatoid arthritis diagnostic agent, an application of the superoxide reductase IV in the preparation of the rheumatoid arthritis diagnostic agent and an application of the superoxide reductase IV in the preparation of a rheumatoid arthritis specific antigen. The superoxide reductase IV has high specificity and sensitivity and is particularly suitable for the application of the early diagnosis agent. The superoxide reductase IV also provides a new idea for the preparation of the rheumatoid arthritis vaccine.

Description

Technical field [0001] The invention involves the medical field and specially involves rheumatoid arthritis special antigen. Background technique [0002] Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by synovitis as the basic pathological change, characterized by chronic destructive arthritis, and most of the diseases are performed.Severe disability, seriously affecting the quality of life of patients.Rheumatoid arthritis that is not treated correctly can not be healed, and even lead to joint malformations.As an autoimmune disease, the reactive CD4 of the pathogenic antigen driver + T cell activation is the core path of rheumatoid arthritis. [0003] For the diagnosis of rheumatoid arthritis, the mainstream still uses the classification standard of RA in the 1987 American Rheumatology Society of Rheumatology. It mainly relies on clinical manifestations and excludes other arthritis to judge RA.In addition, X -ray changes and rheumatoid factors are also ...

AI Technical Summary

Problems solved by technology

[0005]In the early diagnostic indicators, there is a relationship between the increase of IL-8 and IL-6 levels in CMV DNA-positive rheumatoid arthritis patients and the appearance of CMV genome Linked, but low specificity and sensitivity

In terms of RA autoantibodies as detection indicators: Rheumatoid factor (RF) has the disadvantage of low sensitivity; 53.3% of patients with early RF-negative rheumatoid arthritis were positive for anti-perinuclear factor (APF), but APF antigen The storage time of tablets is short (only 1-2 weeks), and the detection stability is low; the positive rate of Sa antibody in rheumatoid arthritis is 40%, and the specificity is 98.9%, but only about 23% in the early stage of rheumatoid arthritis ; No one has reported the correlation between peroxide reductase Ⅳ (referred to as "Ⅳ" in the accompanying drawings) and rheumatoid arthritis

Images